𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies

✍ Scribed by Goldwasser, Francois; Faivre, Sandrine; Alexandre, Jerome; Coronado, Cinthya; Fernández-García, Eva M.; Kahatt, Carmen M.; Paramio, Pilar García; Dios, Jorge Luis Iglesias; Miguel-Lillo, Bernardo; Raymond, Eric

Book ID
121579491
Publisher
Springer US
Year
2014
Tongue
English
Weight
267 KB
Volume
32
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine combined with carboplatin in
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : A multicentric Phase II study
✍ Adolfo G. Favaretto; Savina M. L. Aversa; Adriano Paccagnella; Vincenzo De Pangh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie